Amgen INC Form 4 insider transactions

Director Robert Eckert reports acquisition of Amgen common stock and dividend equivalents through vested restricted stock units and dividend reinvestment.

Director Brian Druker reports acquisition of 719 shares of Amgen common stock on May 31, 2024, through vested Restricted Stock Units (RSUs) and dividend equivalents.

Director Michael V. Drake reports acquiring 719 shares of Amgen common stock on May 31, 2024, through vested Restricted Stock Units (RSUs) under the company's director incentive program.

Director Wanda M. Austin reports acquiring 719 shares of Amgen Inc. common stock on May 31, 2024, through the vesting of restricted stock units.

EVP of Operations at Amgen, Esteban Santos, reports acquisition of stock and option awards.

David M. Reese, EVP & Chief Technology Officer of Amgen, reports the acquisition of stock and option awards.

Derek Miller, SVP of Human Resources at Amgen, reports the acquisition of stock and option awards.

Rachna Khosla, SVP of Business Development at Amgen, reports the acquisition of restricted stock units and non-qualified stock options.

Nancy Grygiel, SVP & CCO of Amgen, reports the acquisition of restricted stock units and non-qualified stock options.

Peter Griffith, EVP & CFO of Amgen, reports the acquisition of restricted stock units and non-qualified stock options.

Jonathan P. Graham, EVP & General Counsel & Secretary of Amgen Inc., reports the acquisition of stock and option awards.

Murdo Gordon, EVP at Amgen, reports the acquisition of stock and options, including restricted stock units (RSUs) and non-qualified stock options (NQSOs).

Matthew C. Busch, VP of Finance & CAO at Amgen, reports the acquisition of restricted stock units and non-qualified stock options.

James E. Bradner, EVP, R&D, & Chief Sci. Officer of Amgen, reports the acquisition of stock and option awards.

Amgen's CEO, Robert Bradway, reports acquisition of shares and stock options, including restricted stock units (RSUs) and non-qualified stock options (NQSOs).

Director Omar Ishrak reports acquiring 116.5501 shares of Amgen common stock on May 7, 2024.

Director Charles M. Holley reports acquiring Amgen common stock through restricted stock units and dividend equivalents.

Director Michael V. Drake reports acquiring Amgen common stock through vested Restricted Stock Units and dividend equivalents.

Esteban Santos, EVP of Operations at Amgen, reports a transaction involving common stock and derivative securities, including the acquisition of shares under the company's 401(k) plan and disposition of shares for tax purposes.

David M. Reese, EVP & Chief Technology Officer of Amgen, disposed of 633 shares of common stock on May 5, 2024, to cover tax obligations.

Amgen's SVP of Human Resources, Derek Miller, disposed of 78 shares of common stock on May 5, 2024, to cover tax obligations related to vested restricted stock units.

Rachna Khosla, SVP of Business Development at Amgen, disposed of 41 shares of common stock on May 5, 2024, to satisfy tax obligations related to vested restricted stock units.

Nancy Grygiel, SVP & CCO of Amgen, reports a transaction involving common stock and holdings in the company's 401(k) plan.

Peter H. Griffith, EVP & CFO of Amgen Inc., reported the disposal of 648 shares of common stock on May 5, 2024, to cover tax obligations related to vested Restricted Stock Units (RSUs).

Jonathan P. Graham, EVP & General Counsel & Secretary of Amgen Inc., reports disposing of 632 shares of common stock to cover tax obligations related to vested Restricted Stock Units.

EVP Murdo Gordon reports disposition of Amgen stock to cover tax obligations related to vesting restricted stock units.

Matthew C. Busch, VP, Finance & CAO of Amgen Inc., reports a transaction involving common stock on May 5, 2024.

Amgen's CEO, Robert Bradway, disposed of 2,220 shares of common stock on May 5, 2024, to cover tax obligations.

Rachna Khosla, SVP of Business Development at Amgen, reports a transaction involving common stock related to tax obligations on vested Restricted Stock Units (RSUs).

Matthew C. Busch, VP, Finance & CAO of Amgen Inc., reports changes in beneficial ownership of Amgen common stock due to the disposition of shares to cover tax obligations related to vesting restricted stock units.